Catalyst Pharmaceuticals

Catalyst is developing amifampridine phosphate for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that amifampridine phosphate has the potential to treat other neuromuscular disorders such as congenital myasthenic syndromes and some cases of myasthenia gravis that are refractory to currently approved therapies.
Type
Public
HQ
Coral Gables, US
Founded
2002
Size (employees)
18 (est)-21%
Catalyst Pharmaceuticals was founded in 2002 and is headquartered in Coral Gables, US

Catalyst Pharmaceuticals Office Locations

Catalyst Pharmaceuticals has an office in Coral Gables
Coral Gables, US (HQ)
1250 355 Alhambra Cir

Catalyst Pharmaceuticals Metrics

Catalyst Pharmaceuticals Financial Metrics

Net income (2016)

($18.1 m)

Market capitalization (28-Apr-2017)

$152.7 m

Closing share price (28-Apr-2017)

$1.8

Cash (31-Dec-2016)

$13.9 m
Catalyst Pharmaceuticals's current market capitalization is $152.7 m.
Catalyst Pharmaceuticals's revenue was reported to be $0 in FY, 2016
FY, 2014FY, 2015FY, 2016

Revenue

Operating expense total

$14.6 m$20.4 m$19.3 m

EBIT

($14.6 m)($20.4 m)($19.3 m)

Pre tax profit

($15.5 m)($20.2 m)($18.1 m)

Income tax expense

Net Income

($15.5 m)($20.2 m)($18.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$2.2 m$9.1 m$28.2 m$13.9 m

Accounts Receivable

Inventories

$4.6 m$1.5 m$1 m

Current Assets

$25.3 m$43.8 m$59.9 m$41.5 m

PP&E

$40.6 k$71.4 k$191.5 k$244.2 k

Total Assets

$25.4 m$43.9 m$60.1 m$41.7 m

Accounts Payable

$850.8 k$1.8 m$1.8 m$933.2 k

Current Liabilities

$2.1 m$5.9 m$3.4 m$2.1 m

Additional Paid-in Capital

$75.7 m$105 m$145.5 m$147.4 m

Retained Earnings

($69.8 m)($90.1 m)($108.1 m)

Total Equity

$21.4 m$35.2 m$55.5 m$39.3 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($12.2 m)($15.5 m)($20.2 m)($18.1 m)

Depreciation and Amortization

$22.5 k$26.6 k$34.5 k$43.4 k

Accounts Receivable

Inventories

Accounts Payable

($514.9 k)$963.4 k($20.1 k)($861 k)

Cash From Operating Activities

($9.9 m)($12.9 m)($18 m)($18 m)

Capital Expenditures

($9.4 k)($57.3 k)($23.5 k)($96.1 k)

Cash From Investing Activities

($7.5 m)($8.7 m)($6.5 k)$3.6 m

Cash From Financing Activities

$18.2 m$28.6 m$37.2 m$69 k

Free Cash Flow

($9.9 m)($12.9 m)($18 m)($17.9 m)

Catalyst Pharmaceuticals Market Value History

Catalyst Pharmaceuticals Online Presence

Catalyst Pharmaceuticals Company Life

You may also be interested in